metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Pirfenidone induces translocation of sirt1 to nucleus and deacetylation of histo...
Journal Information
Vol. 29. Issue S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(February 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(February 2024)
Full text access
Pirfenidone induces translocation of sirt1 to nucleus and deacetylation of histone 3 slows down the development of fibrosis and tumorigenicity in a experimental model of hepatocarcinoma.
Visits
157
Hugo C. Monroy-Ramírez1, Scarlet Arceo-Orozco1, Araceli G. Rivera-Cabral1, Marina Galicia-Moreno1, Juan Armendáriz-Borunda1,2
1 Instituto de Biología Molecular en Medicina y Terapia Génica, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara, México
2 Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey campus Guadalajara, Zapopan, México
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Special issue
This article is part of special issue:
Vol. 29. Issue S2

Abstracts Asociación Mexicana del Hígado (AMH) 2023

More info
Introduction and objectives

Hepatocellular carcinoma (HCC) is the most common liver neoplasm worldwide. Pro-inflammatory and pro-fibrogenic processes are key in tumor development. On the other hand, Pirfenidone (PFD) has anti-inflammatory and antifibrogenic properties useful to counteract hepatocarcinogenesis; however, the effects of this drug on SIRT1, and histone H3 regulation in this disease are unknown.

The objective this work is evaluate PFD effects on SIRT1 translocation, and histone H3 lysines 9 and 14 (H3K9 and H3K14) deacetylation in an experimental model of HCC.

Materials and Patients

Fischer-344 rats were divided into three groups: CTL: control group, HCC: group damaged with diethylnitrosamine (DEN), 50 mg/kg and 2-aminofluorene (2AAF), 25 mg/kg/p.o. HCC/PFD group: damage group and with PFD (300 mg/kg/day) for 16 weeks. Histological and molecular analyzes were performed evaluating patterns of protein acetylation, fibrosis, and malignancy.

Results

Normal liver architecture is disturbed by dysplastic nodules formation surrounded by extracellular matrix and fibrosis, also an increase in cells with anaplasia and steatotic foci was observed in liver tissues of HCC group. PFD administration was effective to prevent these changes. Immunohistochemistry reveals an overexpression of GPC3 and α-SMA in damage group, which is correlated with malignant degeneration, these responses was prevented by PFD too. Finally, western blots evidence a SIRT1 overexpression in nuclear fraction of PFD group, triggering H3K9 and H3K14 deacetylation, in addition, a decrease in p300 acetylase expression in nuclear fractions. Notably, c-Myc was reduced and p53 increased significantly.

Conclusions

PFD treatment reduces fibrotic and malignant patterns development. Likewise, PFD induces SIRT1 expression and nuclear translocation, and H3K9 and H3K14 deacetylation, decompacting chromatin and possibly increasing tumor suppressor genes expression for example c-MYC. These results demonstrate for the first time the capability of PFD to regulate epigenetic hallmarks on histones.

Full Text

Ethical statement

All the experiments were carried out in accordance with the guidelines approved by the Ethics, Research and Biosafety committees of the CUCS with approval number CI-03020.

Declaration of interests

None

Funding

Programa de Fortalecimiento de Institutos, Centros y Laboratorios de Investigación 2022, otorgado al Instituto de Biología Molecular en Medicina y Terapia Génica Programa para el Desarrollo Profesional Docente, para el Tipo Superior (PRODEP), Apoyo a Nuevos Profesores de Tiempo Completo, 511-6/2020-8586 PTC-1534. Fondo para Proyectos de Impulso a la Investigación (PIN 2020- I).

Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos